Cargando…

Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults

Objective: Fexofenadine is a probe drug used to phenotype P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 activities. This study evaluated a limited sampling strategy using plasma concentrations and/or partial area under the concentration versus time curves (AUCs) to es...

Descripción completa

Detalles Bibliográficos
Autores principales: Liyanage, Marlon, Blaquera, Chelsea L., Piscitelli, Joseph, Penzak, Scott R., Nolin, Thomas D., Paine, Mary F., Ma, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339714/
https://www.ncbi.nlm.nih.gov/pubmed/37042268
http://dx.doi.org/10.5414/CP204380
_version_ 1785071906455552000
author Liyanage, Marlon
Blaquera, Chelsea L.
Piscitelli, Joseph
Penzak, Scott R.
Nolin, Thomas D.
Paine, Mary F.
Ma, Joseph D.
author_facet Liyanage, Marlon
Blaquera, Chelsea L.
Piscitelli, Joseph
Penzak, Scott R.
Nolin, Thomas D.
Paine, Mary F.
Ma, Joseph D.
author_sort Liyanage, Marlon
collection PubMed
description Objective: Fexofenadine is a probe drug used to phenotype P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 activities. This study evaluated a limited sampling strategy using plasma concentrations and/or partial area under the concentration versus time curves (AUCs) to estimate systemic exposure and, potentially, P-gp and OATP1B1/3 activities. Materials and methods: Plasma concentration versus time data were obtained from 53 healthy adult participants (22 females) from four published studies. Participants were administered a single oral dose (120 mg) of fexofenadine during constitutive P-gp and OATP1B1/3 conditions. Concentration-time data were divided into a training (n = 18) and validation (n = 35) set. Backwards stepwise linear regression generated single-, 2-timepoint, and partial AUC limited sampling models (LSMs). Noncompartmental analysis methods were used to determine total AUC (AUC(0–lNF)) from intensive sampling. Coefficient of determination (r(2)) and bias and precision were assessed via relative percent mean prediction error (%MPE), relative percent mean absolute error (%MAE), and relative percent root mean square error (%RMSE). Results: The geometric mean observed AUC(0–INF) was 1,680 ng×h/mL. The 2-, 5-, and 2- plus 5-hour LSMs met backwards stepwise linear regression significance (p < 0.15) to remain in the model but had unacceptable %RMSE (17 – 29%). The majority of partial AUC LSMs had unacceptable r(2) (0.21 – 0.83), with all models having unacceptable %MAE (12 – 35%). Conclusion: Fexofenadine limited sampling strategy using single-timepoint, 2-timepoint, and partial AUCs were unable to accurately estimate AUC(0–lNF) and thus constitutive P-gp and OATB1B1/3 activities in healthy adults. Timepoints that were not measured or selected may have improved LSM performance.
format Online
Article
Text
id pubmed-10339714
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-103397142023-07-14 Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults Liyanage, Marlon Blaquera, Chelsea L. Piscitelli, Joseph Penzak, Scott R. Nolin, Thomas D. Paine, Mary F. Ma, Joseph D. Int J Clin Pharmacol Ther Research Article Objective: Fexofenadine is a probe drug used to phenotype P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 activities. This study evaluated a limited sampling strategy using plasma concentrations and/or partial area under the concentration versus time curves (AUCs) to estimate systemic exposure and, potentially, P-gp and OATP1B1/3 activities. Materials and methods: Plasma concentration versus time data were obtained from 53 healthy adult participants (22 females) from four published studies. Participants were administered a single oral dose (120 mg) of fexofenadine during constitutive P-gp and OATP1B1/3 conditions. Concentration-time data were divided into a training (n = 18) and validation (n = 35) set. Backwards stepwise linear regression generated single-, 2-timepoint, and partial AUC limited sampling models (LSMs). Noncompartmental analysis methods were used to determine total AUC (AUC(0–lNF)) from intensive sampling. Coefficient of determination (r(2)) and bias and precision were assessed via relative percent mean prediction error (%MPE), relative percent mean absolute error (%MAE), and relative percent root mean square error (%RMSE). Results: The geometric mean observed AUC(0–INF) was 1,680 ng×h/mL. The 2-, 5-, and 2- plus 5-hour LSMs met backwards stepwise linear regression significance (p < 0.15) to remain in the model but had unacceptable %RMSE (17 – 29%). The majority of partial AUC LSMs had unacceptable r(2) (0.21 – 0.83), with all models having unacceptable %MAE (12 – 35%). Conclusion: Fexofenadine limited sampling strategy using single-timepoint, 2-timepoint, and partial AUCs were unable to accurately estimate AUC(0–lNF) and thus constitutive P-gp and OATB1B1/3 activities in healthy adults. Timepoints that were not measured or selected may have improved LSM performance. Dustri-Verlag Dr. Karl Feistle 2023-06 2023-04-12 /pmc/articles/PMC10339714/ /pubmed/37042268 http://dx.doi.org/10.5414/CP204380 Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liyanage, Marlon
Blaquera, Chelsea L.
Piscitelli, Joseph
Penzak, Scott R.
Nolin, Thomas D.
Paine, Mary F.
Ma, Joseph D.
Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
title Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
title_full Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
title_fullStr Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
title_full_unstemmed Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
title_short Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
title_sort limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339714/
https://www.ncbi.nlm.nih.gov/pubmed/37042268
http://dx.doi.org/10.5414/CP204380
work_keys_str_mv AT liyanagemarlon limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults
AT blaquerachelseal limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults
AT piscitellijoseph limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults
AT penzakscottr limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults
AT nolinthomasd limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults
AT painemaryf limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults
AT majosephd limitationsoffexofenadinelimitedsamplingstrategyusingplasmaconcentrationsandpartialareaundertheconcentrationtimecurvetoestimatetransporteractivityinhealthyadults